Inspiration Healthcare Withdraws AGM Resolutions 10 and 11 After Key Shareholder Input

Details of Withdrawn Resolutions and Their Objectives

Inspiration Healthcare Group plc announced the removal of two special resolutions from its upcoming Annual General Meeting. Resolution 10 aimed to grant the Board flexibility to disapply pre-emption rights on equity securities issued for cash, while Resolution 11 sought to renew the authority for the Company to repurchase its own ordinary shares. Both resolutions were intended to enhance the Company’s operational and strategic flexibility but have now been excluded from the AGM agenda.

Initially, the Board believed these authorities would benefit the Company. However, after receiving input from a major shareholder post-AGM notice publication, the Board chose to withdraw them. This significant change highlights the Company’s commitment to engaging with key investors and adapting its AGM agenda accordingly, just days before the 23 July 2026 meeting.

Effect on AGM Agenda and Shareholder Voting

The Company has confirmed that removing Resolutions 10 and 11 does not invalidate the AGM notice, proxy forms, or votes already submitted for other resolutions. The AGM arrangements and resolution numbering remain unchanged, providing clarity and continuity for shareholders who have prepared to participate or voted in advance.

While the Company has not disclosed the specific concerns from the significant shareholder, the streamlined agenda aims to address investor feedback and ensure a smooth AGM. The meeting will proceed at 12:00 p.m. UK time on 23 July 2026 at the Company’s registered office in Croydon without the two withdrawn resolutions.

Ongoing Business Strategy and Operational Stability

Inspiration Healthcare Group plc emphasises that the withdrawal of these resolutions does not alter its strategic direction or day-to-day operations. As a global leader in neonatal intensive care medical devices, the Company continues to focus on designing, manufacturing, and marketing life-saving products for premature infants and neonatal intensive care units worldwide.

The Board also indicated it does not foresee a need to exercise the authorities that would have been granted by Resolutions 10 and 11 before the next annual general meeting. If circumstances change, a separate shareholder meeting would be convened to seek approval, preserving strategic flexibility while respecting shareholder governance.

Global Market Presence and Product Range

Inspiration Healthcare Group plc maintains a significant global footprint in the neonatal intensive care device market. Its portfolio includes proprietary and distributed products tailored for neonatal care, ranging from advanced ventilators to single-use disposables, supporting hospitals and healthcare providers throughout patient stays.

The Company sells directly in the UK and Ireland and distributes advanced infusion therapy technologies. It has an extensive network of distribution partners covering over 75 countries. Manufacturing operations are based in Croydon, South London, and Melbourne, Florida, supporting international delivery and innovation.

Neonatal Intensive Care Sector Focus and Expertise

Operating in the specialized neonatal intensive care medical devices sector, Inspiration Healthcare addresses critical healthcare needs for premature and vulnerable newborns. This market demands rigorous regulatory compliance, specialized clinical knowledge, and long development cycles. The Company’s integrated approach combining capital equipment, disposables, and complementary products reflects the complex needs of neonatal care worldwide.

Importance of Shareholder Engagement and Governance

The withdrawal of Resolutions 10 and 11 underscores the evolving landscape of shareholder governance among UK-listed companies and the value of board-shareholder dialogue. Inspiration Healthcare’s responsiveness to significant shareholder feedback prior to the AGM demonstrates a governance model prioritizing engagement and consensus.

This approach aligns with broader corporate governance trends emphasizing early shareholder communication to preempt dissent. While some investors may question the withdrawal of authorities deemed beneficial by the Board, the decision highlights the Company’s commitment to transparent and collaborative governance.

Pre-Emption Rights and Equity Issuance Authority

Resolution 10, now withdrawn, related to disapplying pre-emption rights, which protect existing shareholders by requiring new shares offered for cash to be first offered proportionally to them. Removing this protection would have allowed the Board to issue equity capital more rapidly without prior shareholder offer, facilitating fundraising or acquisitions.

The withdrawal indicates shareholder concerns over potential dilution and capital allocation, maintaining existing pre-emption protections. Future equity issuances for cash will require specific shareholder approval or proceed under current authorities, ensuring shareholder safeguards but potentially limiting rapid capital raising.

Share Buyback Authority and Capital Allocation

Resolution 11, also withdrawn, sought to renew the Company’s authority to repurchase its own shares, a common tool for returning capital, supporting employee schemes, or managing share metrics. The withdrawal suggests shareholder reservations about granting unrestricted buyback powers at this time, possibly reflecting capital allocation priorities or financial considerations.

Without renewed authority, share repurchases will require shareholder approval in future meetings. The Company does not currently anticipate needing this authority before the next AGM, indicating buybacks are not an immediate priority.

Regulatory Compliance and Disclosure

The withdrawal of Resolutions 10 and 11 was conducted in accordance with AIM Rules and UK corporate governance standards. The Company issued a clear announcement via the Regulatory News Service (RNS), ensuring transparency and regulatory compliance. The notice includes full AGM details and contact information for shareholder inquiries.

No regulatory breaches are indicated, and the withdrawal is a Board governance decision. Market participants will monitor whether these changes affect the Company’s ability to raise capital, pursue acquisitions, or return capital, and whether these matters return to shareholders in future meetings.

AGM Timeline and Investor Outlook

The AGM is scheduled for 23 July 2026 at 12:00 p.m. UK time, with the withdrawal of Resolutions 10 and 11 occurring just three days prior. Proxy votes already submitted remain valid for the other resolutions, which are unchanged. All AGM arrangements proceed as previously communicated.

Investors should watch for updates on the Company’s capital strategy and any future requests for equity issuance or buyback authorities. While not anticipated before the next AGM, any such requests will require separate shareholder approval, potentially affecting the timing of strategic initiatives in the dynamic medical device sector.